MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in Progress

被引：14

作者：

Strickler, John H. ^{[1
]}

Nakamura, Yoshiaki ^{[2
]}

Yoshino, Takayuki ^{[3
]}

Catenacci, Daniel V. T. ^{[4
]}

Janjigian, Yelena Y. ^{[5
]}

Barzi, Afsaneh ^{[6
]}

Bekaii-Saab, Tanios S. ^{[7
]}

Lenz, Heinz-Josef ^{[8
]}

Lee, Jeeyun ^{[9
]}

Van Cutsem, Eric ^{[10
,11
]}

Chung, Hyun Cheol ^{[12
]}

Alsina, Maria ^{[13
,14
]}

Siena, Salvatore ^{[15
]}

Mayor, Joal Garrido ^{[16
]}

Palanca-Wessels, Maria Corinna ^{[17
]}

Feng Wentao ^{[17
]}

Marshall, John ^{[18
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC USA

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Chicago, Med Ctr, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] City Hope Comprehens Canc Ctr, Duarte, CA USA

[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA

[8] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[9] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med,Samsung Med Ctr, Seoul, South Korea

[10] Univ Hosp Gasthuisberg, Leuven, Belgium

[11] Univ Leuven, Leuven, Belgium

[12] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[13] Vall dHebron Univ Hosp, Barcelona, Spain

[14] Inst Oncol VCIO, Barcelona, Spain

[15] Azienda Socio Sanit Terr Niguarda, Milan, Italy

[16] Seattle Genet, Bothell, WA USA

[17] Seattle Genet Inc, Bothell, WA USA

[18] Georgetown Univ, Washington, DC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.TPS252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS252

引用

页数：3

共 50 条

[1] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress
Catenacci, Daniel V. T.
Strickler, John H.
Nakamura, Yoshiaki
Shitara, Kohei
Janjigian, Yelena Y.
Barzi, Afsaneh
Bekaii-Saab, Tanios S.
Lenz, Heinz-Josef
Chung, Hyun Cheol Cheol
Tabernero, Josep
Yoshino, Takayuki
Siena, Salvatore
Mayor, Joal Garrido
Palanca-Wessels, Maria Corinna
Xie, Diqiong
Marshall, John
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2] MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Catenacci, D. V.
Strickler, J. H.
Shitara, K.
Nakamura, Y.
Janjigian, Y. Y.
Barzi, A.
Bekaii-Saab, T.
Lenz, H. J.
Chung, H. C.
Tabernero, J.
Yoshino, T.
Siena, S.
Mayor, J. G.
Palanca-Wessels, M. C.
Xie, D.
Marshall, J. L.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1071 - S1072
[3] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
Tabernero, J.
Strickler, J.
Nakamura, Y.
Shitara, K.
Janjigian, Y.
Barzi, A.
Bekaii-Saab, T.
Lenz, H.
Yoshino, T.
Siena, S.
Garrido-Mayor, J.
Ubowski, M.
Xie, D.
Marshall, J.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S305 - S306
[4] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
Strickler, J.
Nakamura, Y.
Shitara, K.
Catenacci, D.
Janjigian, Y.
Barzi, A.
Bekaii-Saab, T.
Lenz, H.
Lee, J.
Van Cutsem, E.
Chung, H.
Tabernero, J.
Yoshino, T.
Siena, S.
Garrido-Mayor, J.
Palanca-Wessels, M.
Xie, D.
Marshall, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S159 - S159
[5] Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+gastroesophageal cancer (GEC)
Tehfe, M.
Lee, J.
Rha, S. Y.
Nakamura, Y.
Tabernero, J.
Shitara, K.
Oh, D-Y.
Eads, J.
Marshall, J.
Wainberg, Z. A.
Lee, K-W.
Kang, Y-K.
Liao, C-Y.
Oh, S. Y.
Yeh, K-H.
Richards, D.
Ubowski, M. M.
Zhao, K.
Bhaumik, S.
Strickler, J. H.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S857 - S858
[6] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Cecchini, Michael
Cleary, James M.
Shyr, Yu
Chao, Joseph
Uboha, Nataliya
Cho, May
Shields, Anthony
Pant, Shubham
Goff, Laura
Spencer, Kristen
Kim, Edward
Stein, Stacey
Kortmansky, Jeremy S.
Canosa, Sandra
Sklar, Jeffrey
Swisher, Elizabeth M.
Radke, Marc
Ivy, Percy
Boerner, Scott
Durecki, Diane E.
Hsu, Chih-Yuan
Lorusso, Patricia
Lacy, Jill
[J]. BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 476 - 482
[7] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini
James M. Cleary
Yu Shyr
Joseph Chao
Nataliya Uboha
May Cho
Anthony Shields
Shubham Pant
Laura Goff
Kristen Spencer
Edward Kim
Stacey Stein
Jeremy S. Kortmansky
Sandra Canosa
Jeffrey Sklar
Elizabeth M. Swisher
Marc Radke
Percy Ivy
Scott Boerner
Diane E. Durecki
Chih-Yuan Hsu
Patricia LoRusso
Jill Lacy
[J]. British Journal of Cancer, 2024, 130 : 476 - 482
[8] Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
Al-Batran, S. -E.
Van Cutsem, E.
Oh, S. C.
Bodoky, G.
Shimada, Y.
Hironaka, S.
Sugimoto, N.
Lipatov, O. N.
Kim, T. -Y.
Cunningham, D.
Rougier, P.
Muro, K.
Liepa, A. M.
Chandrawansa, K.
Emig, M.
Ohtsu, A.
Wilke, H.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 673 - 679
[9] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
Rha, Sun Young
Kim, Chang Gon
Jung, Minkyu
Kim, Hyo Song
Lee, Choong-kun
Jeung, Hei-Cheul
Koo, Dong-Hoe
Bae, Woo Kyun
Zang, Dae Young
Kim, Hyunki
Chung, Hyun Cheol Cheol
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
Stinchcombe, Tom
Monk, Bradley J.
Okines, Alicia Frances Clare
Pohlmann, Paula R.
Yu, Evan Y.
Bekaii-Saab, Tanios S.
Nakamura, Yoshiaki
O'Malley, David M.
Kang, Vicky
Walker, Luke N.
Reck, Martin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →